Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300

Cancer

Volumn 86, Issue 4, 1999, Pages 689-696

  Sun, Zijie ^a   Pan, Jing ^b   Hope, WeiQiao Xie ^a   Cohen, Stanley N ^a   Balk, Steven P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen receptor; CBP P300; Prostate carcinoma; Steroid hormone receptor; Tumor susceptibility gene 101 (TSG101)

Indexed keywords

ANDROGEN RECEPTOR; HYBRID PROTEIN; TRANSCRIPTION FACTOR;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; DNA BINDING; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TRANSACTIVATION;

ANIMALS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASM PROTEINS; ONCOGENES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 0033567068     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990815)86:4<689::AID-CNCR19>3.0.CO;2-P     Document Type: Article

References (42)

1. Li L, Cohen SN. Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 1996;85:319-29.
2. Maucuer A, Camonis JH, Sobel A. Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. Proc Natl Acad Sci USA 1995;92:3100-4.
3. Beretta L, Dubois MF, Sobel A, Bensaude O. Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress in HeLa cells. Eur J Biochem 1995;227:388-95.
4. Chneiweiss H, Beretta L, Cordier J, Boutterin MC, Glowinski J, Sobel A. Stathmin is a major phosphoprotein and cyclic AMP-dependent protein kinase substrate in mouse brain neurons but not in astrocytes in culture: regulation during ontogenesis. J Neurochem 1989;53:856-63.
5. Leighton IA, Curmi P, Campbell DG, Cohen P, Sobel A. The phosphorylation of Stathmin by MAP kinase. Mol Cell Biochem 1993;127:151-6.
6. Lin PM, Liu TC, Chang JG, Chen TP, Lin SF. Aberrant TSG101 transcripts in acute myeloid leukaemia. Br J Haematol 1998;102:753-8.
7. Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, et al. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J Soc Gynecol Investig 1998;5:281-5.
8. Oh Y, Proctor ML, Fan YH, Su LK, Hong WK, Fong KM, et al. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene 1998;17:1141-8.
9. Li L, Li X, Francke U, Cohen SN. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 1997;88:143-54.
10. Lee MP, Feinberg AP. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997;57: 3131-4.
11. Sun Z, Pan J, Bubley G, Balk SP. Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 1997;15:3121-5.
12. Hampl M, Hampl J, Plaschke J, Fitze G, Schackert G, Saeger HD, et al. Evidence that TSG101 aberrant transcripts are PCR artifacts. Biochem Biophys Res Commun 1998;248:753-60.
13. Wagner KU, Dierisseau P, Rucker EBr, Robinson GW, Hennighausen L. Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 1998;17: 2761-70.
14. Li L, Francke U, Cohen SN. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer [Retraction of Li L, Li X, Francke U, Cohen SN. In: Cell 1997;88(1):143-54]. Cell 1998;93:following 660.
15. Li L, Francke U, Cohen SN. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer [Retraction of Li L, Li X, Francke U, Cohen SN. In: Cell 1997;88(1):143-54]. Cell 1998;93:following 660.
16. Wang Q, Driouch K, Courtois S, Champeme MH, Bieche I, Treilleux I, et al. Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers, Oncogene 1998;16: 677-9.
17. Xie W, Li L, Cohen SN. Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci USA 1998;95:1595-600.
18. Zhong Q, Chen Y, Jones D, Lee WH. Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 1998;58: 2699-702.
19. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 1989;245:371-8.
20. Koonin EV, Abagyan RA. TSG101 may be the prototype of a class of dominant negative ubiquitin regulators [letter]. Nat Genet 1997;16:330-1.
21. Ponting CP, Cai YD, Bork P. The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med 1997;75: 467-9.
22. Thomson TM, Khalid H, Lozano JJ, Sancho E, Arino J. Role of UEV-1A, a homologue of the tumor suppressor protein TSG101, in protection from DNA damage. FEBS Lett 1998; 423:49-52.
23. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-857.
24. Escriva H, Langlois MC, Mendonca RL, Pierce R, Laudet V. Evolution and diversification of the nuclear receptor superfamily. Ann N Y Acad Sci 1998;839:143-6.
25. Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J, et al. A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 1998; 245:900-5.
26. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner ARE, Ogata GK, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-8.
27. Klemsz MJ, McKercher SR, Celada A, Beveren CV, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets Oncogene. Cell 1990;61:113-24.
28. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-21.
29. Monden T, Wondisford FE, Hollenberg AN. Isolation and characterization of a novel ligand-dependent thyroid hormone receptor-coactivating protein. J Biol Chem 1997;272: 29834-41.
30. Ayer DE, Laherty CD, Lawrence QA, Armstrong AP, Eisenman RN. Mad proteins contain a dominant transcription repression domain. Mol Cell Biol 1996;16:5772-5781.
31. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988;67:31-40.
32. Sterneck E, Muller C, Katz S, Leutz A. Autocrine growth induced by kinase type oncogenes in myeloid cells requires AP-1 and NF-M, a myeloid specific, C/EBP-like factor. EMBO 1992;11:115-26.
33. Lin Y-S, Carey MF, Ptashne M, Green MR. GAL4 derivatives function alone and synergistically with mammalian activators in vitro. Cell 1988;54:659-64.
34. Kadosh D, Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Responsible histone deacetylase to target promoters. Cell 1997;89: 365-71.
35. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997;89:373-80.
36. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997;89:341-7.
37. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, et al. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci U S A 1996;93:11540-5.
38. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, et al. Role of CBP/P300 in nuclear receptor signalling. Nature 1996;383:99-103.
39. Yao TP, Ku G, Zhou N, Scully R, Livingston DM. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 1996;93:10626-31.
40. Bubley GJ, Balk SP. Treatment of metastatic prostate cancer. Lessons from the androgen receptor. Hematol Oncol Clin North Am 1996;10:713-25.
41. Kasten MM, Ayer DE, Stillman DJ. SIN3-dependent transcriptional repression by interaction with the Mad1 DNA-binding protein. Mol Cell Biol 1996;16:4215-21.
42. Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC, et al. Stathmin expression is a feature of proliferating cells of most, if not all, cell lineages. Lab Invest 1995;72:100-13.